Pharma major Novartis falls 9% after three drug trial setbacks
Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.
Read it at CNBC See this on the map
What might happen next? AI-generated
These scenarios are written by an AI language model from the headline and summary above. They are not predictions from the newsroom, and they are not evidence of anything. Every one is given a deadline and checked against later coverage, and the score is published on the ledger — including the ones that miss.
ForecastGeo shows the headline and summary published by the newsroom and places the story on a map. The full article lives at the source.